LMR Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

LMR Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-488	Closed	-$116K	–	586
2017 Q2	$116K	Buy	+488	New	+$111K	0.01%	560
2014 Q3	–	Sell	-30	Closed	-$219K	–	500
2014 Q2	$219K	Buy	+30	New	+$150K	0.02%	385

Other funds holding EIGR

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LMR Partners's EIGR Position: Q3 2017 in Review

LMR Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2017, closing a stake of 488 shares — an estimated $116K sold.

LMR Partners first reported a position in EIGR in Q2 2014 and held it in 2 quarters. The position peaked at $219K in Q2 2014. 33 funds tracked by Wall St. Rank hold EIGR as of Q3 2017.

LMR Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
LMR Partners sold 488 Eiger BioPharmaceuticals, Inc. shares in Q3 2017, an estimated $116K.
LMR Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2014 and held it in 2 quarters.
LMR Partners's Eiger BioPharmaceuticals, Inc. position peaked at $219K in Q2 2014.
33 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2017.

Based on LMR Partners's 13F filing for Q3 2017, filed 9 Nov 2017.